LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects

NCT00833872 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis Vulgaris

Interventions

DRUG: LEO 22811
DRUG: placebo solution

Sponsor

LEO Pharma